Regarding nanomedicines for targeting KRAS-mutated cancers, a lipid nanoparticle comprising an siRNA therapeutic against glutathione S-transferase P (NBF-006) was able to promote a tumor regression and a prolongation in the survival rate of animals in a surgically implanted orthotopic NSCLC tumor model [103]. This evidence concerns the gene KRAS and cancer.